Articles On Immuron (ASX:IMC)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

This week’s Bulls N’ Bears top ASX runner is… Macro Metals. Its share price rose more than 166 per cent to join fellow movers and shakers Immuron, Sultan Resources and Dynamic Metals.

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

The ASX200 closed up 0.4 per cent. Industrials & IT led the ranks – both up more than a per cent – while energy weighed on the market, losing well over 1.1 per cent.   What drove industrials? The standout was a company, Wiseway Gr...

The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy.  Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r...

The ASX200 has been trading up 0.18 per cent to just above 7,745 points – not by the nearly half a per cent tipped before the market opened this morning. The Industrials sector has made the greatest gains, edging up close to a per cent a...

07 Mar 2024 - A snapshot of the stocks on the move, featuring Dotz Nano (ASX:DTZ, OTC:DTZNY), Immuron (ASX:IMC; NASDAQ:IMRN) and Avecho Biotechnology (ASX:AVE).

Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, permanent CEO   Immuron almost doubles on Travelan results Immuron (ASX:IMC) jumped by over 80% this mo...

Australian biopharmaceutical company Immuron (ASX: IMC) has released interim topline results from a US-based clinical trial of lead candidate IMM-124E (Travelan) confirming that a single daily dose can be effective in the prevention of mode...

A little-known ASX healthcare stock is setting the bar sky-high today. In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up 0.2%, while shares in this biopharmaceutical company just rocketed 96.9% to 13 cents apiece. Th...

  To register for Friday's webinar click here. Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale demonstration unit for its carbon capt...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Immuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for benefit of patients   Immuron’s record sales Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January pe...

Immuron (ASX:IMC) has announced record sales of its over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract, Travelan.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Immuron (IMC) announces a 136 per cent increase in FY23 global sales on FY22 sales The sales of its over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn rose from $765,000 in FY22 to $1.80 mill...

Cann Group’s FY23 sales were 2.1 times that of FY22 Immuron’s FY23 sales increased by 136% from the previous year   Cann Group doubles its sales revenue Cannabis house Cann Group (ASX:CAN) rose 8% this morning after releasing its full yea...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

ASX benchmark ends the day flat, but not for lack of trying to rise. Or fall Tech stocks fell hard at first light, but rallied to finish the day well out in front Despite a short-lived challenge from Audio Pixels, Micro-X has won the day i...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received approval from the US FDA to proceed with the clinical evaluation of the new oral therapeutic targeting campylobacter and enterotoxigenic Escheric...

Little Green Pharma gets extended contract from the French government US FDA’s decision paves the way for a clinical involving Immuron’s drug Antisense Therapeutics announces new CEO   Cannabis stock Little Green Pharma (ASX:LGP) has been...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

ShareCafeTech and mining shares lead ASX 0.25% lower at close by Peter Milios   Technology and mining shares led the decline before the Easter break. For the week, the benchmark index recorded a gain of 0.6 per cent, marking its second cons...

Health care stocks have surged in early trade, up more than a per cent. Biotech company Immuron made the most of the boost, with its shares up more than 21 per cent after posting its Q3 FY23 financial figures. Global sales of its trav...

ShareCafeAus shares down 0.25% at noon as RBA warns of higher risk by Peter Milios   The Reserve Bank of Australia’s Financial Stability Review states that while the Australian financial system is strong and able to support economic activit...

Immuron (IMC) shares are rising after posting its Travelan and Protectyn sales figures for Q3 FY23 Global Q3 YTD sales of Travelan and Protectyn have risen by 239 per cent in FY23 to reach $1.46 million In Australia, sales of both pro...

ShareCafeStocks of the Hour: IMC, WMG, CPM                    Australian based and globally integrated biopharmaceutical company, Immuron (ASX:IMC) has announced that their global Q3 year-to-date sales have increased by 239% and their...

06 Apr 2023 - A snapshot of the stocks on the move featuring Immuron (ASX:IMC), Western Mines Group (ASX:WMG) and Cooper Metals (ASX:CPM).

Noxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after saying that ColoSTAT will be presented at a prestigious gathering Immuron surged 24% as global sales rose significantly   Noxopharm (ASX:NOX)...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX is poised to open modestly lower on Thursday Tech stocks plummeted in the US overnight on rotation away from growth shares Citi and BoA predict bullish gold target prices this year   Aussie shares are set to edge modestly lower on...

The ASX is expected to slip on Thursday as eyes are once again on the Reserve Bank. The RBA is expected to deliver its financial stability review in the coming hours, ahead of the Easter long weekend. Here are some ASX-listed companie...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...